Vaginal microflora following the usage of disposable home-use vaginal device, and commercially available ring pessary for pelvic organ prolapse management: A randomized controlled trial

Author:

Ziv Elan1,Keller Nathan,Erlich Tsvia

Affiliation:

1. ConTIPI Medical Ltd

Abstract

Abstract Purpose To investigate whether ProVate™, a novel, disposable, self-inserted vaginal device for pelvic organ prolapse management, clinically affects the vaginal microflora, as compared with a commercially available ring pessary, in order to assess its microbiological safety. Methods This interventional, prospective, multi-center, open-label, randomized, controlled, statistically powered (non-inferiority), home-use, cross-over study was conducted at seven sites. Participants were randomized into either group A (using ProVate™ and then a new reusable commercially available ring pessary [control]) or B (using control device and then ProVate™) with a 1:1 ratio. Primary endpoint was based on meeting one of the failure criteria: significant change in Lactobacillus spp., Gardnerella vaginalis, Candida morphotypes, or Staphylococcus aureus levels compared to the baseline (significant change: Nugent score ≥ 7 or > 1 scale unit increase in S. aureus or Candida morphotype), bothersome vaginal symptoms, or symptoms requiring treatment. Results The study included 58 participants (mean age: 64.5 years, 91.4% post-menopausal). The failure rate was 15.5% for ProVate™ and control groups while using 383 ProVate™ devices over 1,647 days or one control device throughout the study. Two patients had bothersome vaginal complaints and one had vaginal infection in the control group, but no such cases were observed in the ProVate™ group. Conclusion The primary endpoint of possible vaginal microbial changes, bothersome vaginal symptoms, or treatment-requiring vaginal complaints while using ProVate™ was successfully met. Our findings show that the vaginal microflora is comparable when using either ProVate™ or commercially available ring pessary (control) with a relatively low rate of vaginal infections. Trial registration details ClinicalTrials.gov;

Publisher

Research Square Platform LLC

Reference28 articles.

1. International urogynecology consultation Chap. 1 committee 2: epidemiology of pelvic organ prolapse: prevalence, incidence, natural history, and service needs;Brown HW;Int Urogynecol J,2022

2. Forecasting the prevalence of pelvic floor disorders in U.S. Women: 2010 to 2050;Wu JM;Obstet Gynecol,2009

3. The role of the nurse in the use of vaginal pessaries to treat pelvic organ prolapse and/or urinary incontinence: a literature review;McIntosh L;Urol Nurs,2005

4. Impact of pessary use on prolapse symptoms, quality of life, and body image;Patel M;Am J Obstet Gynecol,2010

5. Discontinuation rate and adverse events after 1 year of vaginal pessary use in women with pelvic organ prolapse;Yimphong T;Int Urogynecol J,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3